NEJM study shows Votrient's benefits in Kidney Cancer
Results from a Phase III trial of 1,100 metastatic Kidney Cancer patients comparing Votrient (pazopanib), from Glaxo Smith Kline, with Sutent (sunitinib), are published in the August 22 issue of the New England Journal of Medicine. Median time before the cancer progressed was similar: 8.4 months for Votrient and 9.5 months for sunitinib. Median overall survival was also comparable: 28.4 months for Votrient vs 29.3 months for sunitinib.
However Votrient was rated superior on 11 or 14 measures of quality of life. In addition, Votrient patients had fewer phone consultations with doctors and visited ER less frequently. See: "Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma" Robert J. Motzer et al. N Engl J Med 2013, 369, 722-31. DOI: 10.1056/NEJMoa1303989
Related news and insights
Zai Lab Limited and its partner Entasis Therapeutics Holdings Inc. announced topline results from the ATTACK trial, a global Phase III registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.
Atea Pharmaceuticals, Inc. reported that the global Phase II MOONSONG trial evaluating AT 527 in the outpatient setting did not meet the primary endpoint of reduction from baseline in the amount of SARS-CoV-2 virus in patients with mild or moderate COVID-19 compared to placebo in the overall study population, of which approximately two thirds of patients were low-risk with mild symptoms.